이 애플리케이션의 일부 콘텐츠는 현재 사용할 수 없습니다.
이 상황이 계속되면 다음 주소로 문의하십시오피드백 및 연락
1. (WO2017153939) PHARMACEUTICAL COMPOSITION COMPRISING CANAGLIFLOZIN, PROCESS OF PREPARATION AND USE THEREOF
국제사무국에 기록된 최신 서지정보    정보 제출

공개번호: WO/2017/153939 국제출원번호: PCT/IB2017/051377
공개일: 14.09.2017 국제출원일: 09.03.2017
IPC:
A61K 9/20 (2006.01)
A SECTION A — 생활필수품 농업
61
위생학; 의학 또는 수의학
K
의약용, 치과용 또는 화장용 제제
9
특별한 물리적 형태에 의하여 특징 지어지는 의약품 제제
20
환제, 로젠지(lozenge) 또는 정제
출원인:
BARIK, Satyabrata [IN/IN]; IN
CHOKKASANDRA JAYARAMAREDDY, Venugopala [IN/IN]; IN
MEENAKSHISUNDERAM, Sivakumaran [IN/IN]; IN
AUROBINDO PHARMA LIMITED [IN/IN]; Aurobindo Pharma Limited, The Water Mark Building, Plot No.11, Survey No.9, Kondapur, Hitech City, Hyderabad, Pin - 500 084, Telangana, Hyderabad 500 084, IN
발명자:
BARIK, Satyabrata; IN
CHOKKASANDRA JAYARAMAREDDY, Venugopala; IN
MEENAKSHISUNDERAM, Sivakumaran; IN
일반
대표자:
AUROBINDO PHARMA LIMITED; IN
우선권 정보:
20164100834910.03.2016IN
발명의 명칭: (EN) PHARMACEUTICAL COMPOSITION COMPRISING CANAGLIFLOZIN, PROCESS OF PREPARATION AND USE THEREOF
(FR) COMPOSITION PHARMACEUTIQUE COMPRENANT DE LA CANAGLIFLOZINE, PROCÉDÉ DE PRÉPARATION ET UTILISATION DE CELLE-CI
요약서:
(EN) The present invention relates to a binder free pharmaceutical composition comprising canagliflozin or a prodrug or a pharmaceutically acceptable salt thereof, and one or more 5 pharmaceutically acceptable excipients, wherein the said composition is devoid of canagliflozin hemihydrate, and having acceptable chemical stability, polymorphic stability & comparative dissolution and bioequivalence profile to that of INVOKANA® tablets.
(FR) La présente invention concerne une composition pharmaceutique sans liant comprenant de la canagliflozine ou un promédicament ou sel pharmaceutiquement acceptable de celle-ci, et un ou plusieurs excipients pharmaceutiquement acceptables, où ladite composition est exempte de canaglifozine hémihydratée, et présente un profil acceptable de stabilité chimique, de stabilité polymorphique et de bioéquivalence et dissolution comparative, par rapport à celui des comprimés INVOKANA®.
front page image
지정국: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
아프리카지역 지식재산권기구(ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
유라시아 특허청 (AM, AZ, BY, KG, KZ, RU, TJ, TM)
유럽 특허청(EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
공개언어: 영어 (EN)
출원언어: 영어 (EN)